FindTrial
Sign In

Cross-sectional and longitudinal assessment of uremia-related substances' concentration associated with kidney function in chronic kidney disease patients

Cross-sectional and longitudinal assessment of uremia-related substances' concentration associated with kidney function in chronic kidney disease patients - Cross-sectional and longitudinal assessment ofuremia-related substances' concentration associated with kidney function in chronic kidney disease patients

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000023772
Enrollment
500
Registered
2016-09-01
Start date
2016-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease, stage 3-5

Interventions

None listed

Sponsors

Osaka General Medical Center
Lead Sponsor
Chugai Pharmaceutical Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with CKD (stage 3-5) doing outpatient visits to the department of Kidney Disease and Hypertension, Osaka General Medical Center

Exclusion criteria

Exclusion criteria: Patients with malignant tumor (including hematologic malignancy), hematologic disease, hepatic cirrhosis, severe infection, severe cognitive impairment, or apparent hemorrhagic lesion. Patients who are judged to be inappropriate for the study participants by principal investigator or subinvestigators.

Design outcomes

Primary

MeasureTime frame
Sialidase activity—

Secondary

MeasureTime frame
Erythroferrone, Myostatin, Apelin—

Countries

Japan

Contacts

Public ContactTerumasa Hayashi

Osaka General Medical Center Department of Kidney Disease and Hypertension

t-hayashi@abelia.ocn.ne.jp+81-6-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026